6-氯鸟嘌呤核苷 | 2004-07-1

• 物质功能分类: 生物化工 - 核苷类药物 - 核苷中间体
• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 中文名称: 6-氯鸟嘌呤核苷
• 中文别名: 2-氨基-6-氯-9-(β-D-呋喃核糖基)嘌呤；6-氯腺苷；2-氨基-6-氯嘌呤核苷；6-氯鸟嘌呤核甙；6-氯鸟苷；6-氯鸟嘌呤苷
• 英文名称: 2-Amino-6-chloropurine riboside
• 英文别名: 2-amino-6-chloro-9-(β-D-ribofuranosyl)purine；6-Chloroguanosine；(2R,3R,4S,5R)-2-(2-amino-6-chloropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 2004-07-1
• 化学式: C₁₀H₁₂ClN₅O₄
• 分子量: 301.689
• InChiKey: TXWHPSZYRUHEGT-UUOKFMHZSA-N

物化性质

• 熔点：
  165-167 °C (dec.)(lit.)
• 沸点：
  729.9±70.0 °C(Predicted)
• 密度：
  1.8359 (rough estimate)
• 溶解度：
  可溶于二甲基亚砜、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  140
• 氢给体数：
  4
• 氢受体数：
  8

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  29349990
• 危险品运输编号：
  OTH
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

制备方法与用途

6-氯鸟嘌呤核苷是鸟嘌呤核苷的氯取代物，又称为2-氨基-6-氯嘌呤核苷或2-氨基-6-氯-9-(β-D-呋喃核糖基)嘌呤，是一种重要的化工原料和药物中间体。

反应信息

• 作为反应物：
  描述：

  6-氯鸟嘌呤核苷 在 copper(l) iodide 、 氨 、 碘 、 亚硝酸异戊酯 作用下， 以 四氢呋喃 、 乙二醇甲醚 为溶剂， 反应 42.5h， 生成 (2R,3R,4S,5R)-2-[6-amino-2-(4-aminobutylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
  参考文献：
  名称：

  Adenosine Analogues as Inhibitors of Trypanosoma brucei Phosphoglycerate Kinase:  Elucidation of a Novel Binding Mode for a 2-Amino-N⁶-Substituted Adenosine

  摘要：

  As part of a project aimed at structure-based design of adenosine analogues as drugs against African trypanosomiasis, N-6-, 2-amino-N-6-, and N-2-substituted adenosine analogues were synthesized and tested to establish structure-activity relationships for inhibiting Trypanosoma brucei glycosomal phosphoglycerate kinase (PGK), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and glycerol-3-phosphate dehydrogenase (GPDH). Evaluation of X-ray structures of parasite PGK, GAPDH, and GPDH complexed with their adenosyl-bearing substrates led us to generate a series of adenosine analogues which would target all three enzymes simultaneously. There was a modest preference by PGK for NG-substituted analogues bearing the 2-amino group. The best compound in this series, 2-amino-N-6-[2 "-(p-hydroxyphenyl)ethyl]adenosine (46b), displayed a 23-fold improvement over adenosine with an IC50 of 130 muM. 2-[[2 "-(p-Hydroxyphenyl)ethyl]amino]adenosine (46c) was a weak inhibitor of T. brucei PGK with an IC50 of 500 muM. To explore the potential of an additive effect that having the N-6 and N-2 substitutions in one molecule might provide, the best ligands from the two series were incorporated into N-6,N-2-disubstituted adenosine analogues to yield N-6-(2 " -phenylethyl)-2-[(2 " -phenylethyl)amino]adenosine (69) as a 30 muM inhibitor of T. brucei PGK which is 100-fold more potent than the adenosine template. In contrast, these series gave no compounds that inhibited parasitic GAPDH or GPDH more than 10-20% when tested at 1.0 mM. A 3.0 Angstrom X-ray structure of a T, brucei PGK/46b complex revealed a binding mode in which the nucleoside analogue was flipped and the ribosyl moiety adopted a syn conformation as compared with the previously determined binding mode of ADP. Molecular docking experiments using QXP and SAS program suites reproduced this "flipped and rotated" binding mode.

  DOI：

  10.1021/jm000287a
• 作为产物：
  描述：

  鸟苷 在 氯化亚砜 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 54.0h， 生成 6-氯鸟嘌呤核苷
  参考文献：
  名称：

  新型6-取代氨基-9-（β -d-呋喃核糖基）嘌呤类似物的合成及其对人上皮癌细胞的生物活性

  摘要：

  制备了在C-6位置具有氮取代的新核苷衍生物，并通过NCI-磺胺丁丹B试验初步筛选了它们对人上皮癌细胞（肝Huh7，结肠HCT116，乳腺MCF7）的体外抗癌生物活性。N 6-（4-三氟甲基苯基）哌嗪类似物（27）表现出有希望的细胞毒性活性。 在Huh7，HCT116和MCF7细胞系上，化合物27比5-FU，氟达拉滨具有更高的细胞毒性（IC 50 = 1-4μM）。最有效的核苷（11，13，16，18，19，21，27，（28）进一步筛选了它们在肝细胞癌细胞系中的细胞毒性。化合物27对Huh7，Mahlavu和FOCUS细胞表现出最高的细胞毒活性（IC 50 分别为1、3和1μM）。分子的理化性质，药物相似性和药物得分曲线表明，它们被认为具有口服生物利用度。结果表明，新型衍生物将是潜在的药物候选物。

  DOI：

  10.1016/j.bmcl.2017.12.070

文献信息

• [EN] 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES<br/>[FR] DÉRIVÉS DE NUCLÉOSIDE 2'-SUBSTITUÉS ET PROCÉDÉS D'UTILISATION DE CEUX-CI POUR LE TRAITEMENT DE MALADIES VIRALES
  申请人：MERCK SHARP & DOHME

  公开号：WO2012142085A1

  公开（公告）日：2012-10-18

  The present invention relates to 2'-Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, X, R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising at least one 2'-Substituted Nucleoside Derivative, and methods of using the 2'-Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

  本发明涉及式(I)的2'-取代核苷衍生物及其药学上可接受的盐，其中A、B、X、R1、R2和R3如本文所定义。本发明还涉及包含至少一种2'-取代核苷衍生物的组合物，以及使用这些2'-取代核苷衍生物治疗或预防患者HCV感染的方法。
• 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
  申请人：Girijavallabhan Vinay

  公开号：US20140206640A1

  公开（公告）日：2014-07-24

  The present invention relates to 2′-Azido Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R 1 , R 2 and R 3 are as defined herein. The present invention also relates to compositions comprising at least one 2′-Azido Substituted Nucleoside Derivative, and methods of using the 2′-Azido Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

  本发明涉及式(I)的2'-叠氮基取代核苷衍生物及其药学上可接受的盐，其中B、X、R1、R2和R3如本文所定义。本发明还涉及包含至少一种2'-叠氮基取代核苷衍生物的组合物，以及使用这些2'-叠氮基取代核苷衍生物治疗或预防患者HCV感染的方法。
• [EN] CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS<br/>[FR] DINUCLÉOTIDES CYCLIQUES UTILISÉS EN TANT QU'AGENTS ANTICANCÉREUX
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2019074887A1

  公开（公告）日：2019-04-18

  The present invention is directed to compounds of the formula (I), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

  本发明涉及式(I)的化合物，其中所有取代基在此定义，以及包括本发明化合物的药学上可接受的组合物，以及使用这些组合物治疗各种疾病的方法。
• Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
  申请人：——

  公开号：US20020147160A1

  公开（公告）日：2002-10-10

  The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.

  本发明提供了核苷化合物及其某些衍生物，这些衍生物是RNA依赖性RNA病毒聚合酶的抑制剂。这些化合物是RNA依赖性RNA病毒复制的抑制剂，可用于治疗RNA依赖性RNA病毒感染。它们特别适用于作为丙型肝炎病毒（HCV）NS5B聚合酶的抑制剂，作为HCV复制的抑制剂，以及/或用于治疗丙型肝炎感染。本发明还描述了包含这种核苷化合物的药物组合物，单独使用或与其他对RNA依赖性RNA病毒感染，特别是HCV感染有效的制剂组合使用。还公开了使用本发明的核苷化合物抑制RNA依赖性RNA聚合酶、抑制RNA依赖性RNA病毒复制和/或治疗RNA依赖性RNA病毒感染的方法。
• Pd/PTABS: Low-Temperature Thioetherification of Chloro(hetero)arenes
  作者：Siva Sankar Murthy Bandaru、Shatrughn Bhilare、Jesvita Cardozo、Nicolas Chrysochos、Carola Schulzke、Yogesh S. Sanghvi、Krishna Chaitanya Gunturu、Anant R. Kapdi

  DOI：10.1021/acs.joc.9b00840

  日期：2019.7.19

  Heteroarenes of commercial relevance such as purines and pyrimidines were also found to be useful substrates for the reported transformation. The commercial drug Imuran (azathioprine) was synthesized as an example, and its preparation could be optimized. DFT studies were performed to understand the electronic effects of the tested ligands on the catalytic reaction.

  杂芳基氯化物的硫醚化是必不可少的合成方法，可用于获得生物活性药物和农药。由于它们的（实际或潜在的）工业重要性，出于经济和生态方面的原因，需要开发一种有效的低温协议来获取这些化合物。因此，开发了一种仅在50°C下使用Pd / PTABS系统的高效催化方案。高效率地进行了氯杂芳烃与各种反应性较低的芳基硫醇和烷基硫醇之间的偶联。还发现具有商业意义的杂芳烃，例如嘌呤和嘧啶，是报道的转化的有用底物。以合成的商品药物Imuran（硫唑嘌呤）为例，可以优化其制备方法。

表征谱图